VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial

被引:4
作者
Coffman-D'Annibale, Kelley [1 ]
Myojin, Yuta [1 ]
Monge, Cecilia [1 ]
Xie, Changqing [1 ]
Hrones, Donna Mabry [1 ]
Wood, Bradford J. [2 ,3 ]
Levy, Elliot B. [2 ,3 ]
Kleiner, David [4 ]
Figg, William Douglas [5 ]
Steinberg, Seth M. [6 ]
Redd, Bernadette [7 ]
Greten, Tim F. [1 ,8 ]
机构
[1] NCI, Ctr Canc Res, Gastrointestinal Malignancies Sect, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Intervent Oncol Radiol & Imaging Sci, Clin Ctr, Bethesda, MD USA
[3] NIH, Ctr Canc Res, Bethesda, MD USA
[4] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD USA
[5] NCI, Mol Pharmacol Sect, Ctr Canc Res, NIH, Bethesda, MD USA
[6] NCI, Biostat & Data Management Sect, Ctr Canc Res, NIH, Bethesda, MD USA
[7] NCI, Radiol & Imaging Sci, Ctr Canc Res, NIH, Bethesda, MD USA
[8] NCI, Liver Canc Program, NIH, Bethesda, MD 20814 USA
基金
美国国家卫生研究院;
关键词
Immunotherapy; Tumor Microenvironment; Gastrointestinal Neoplasms; Liver Neoplasms; Oncolytic Virotherapy; VESSEL CO-OPTION; GENE-THERAPY; CANCER; RESISTANCE; VACCINE; SAFETY;
D O I
10.1136/jitc-2023-008079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMicrosatellite stable colorectal liver metastases (MSS CLM) maintain an immunosuppressive tumor microenvironment (TME). Historically, immune-based approaches have been ineffective. VB-111 (ofranergene obadenovec) is a genetically-modified adenoviral vector targeting the TME; its unique dual mechanism induces an immune response and disrupts neovascularization. Checkpoint inhibition may synergize the immune response induced by viral-mediated anti-angiogenic gene therapy. We aimed to examine the safety and antitumor activity of VB-111 and nivolumab in patients with refractory MSS CLM and to characterize immunological treatment-response.MethodsThis was a phase II study of adult patients with histologically-confirmed MSS CLM who progressed on prior therapy. A priming dose of VB-111 1x1013 viral particles was given intravenously 2 weeks prior to starting biweekly nivolumab 240 mg and continued every 6 weeks. The combination continued until disease progression or unacceptable toxicity. The primary objectives were overall response rate and safety/tolerability. Secondary objectives included median overall survival and progression-free survival. Correlative studies were performed on paired tumor biopsies and blood.ResultsBetween August 2020 and December 2021, 14 patients were enrolled with median age 50.5 years (40-75), and 14% were women. Median follow-up was 5.5 months. Of the 10 evaluable patients, the combination of VB-111 and nivolumab failed to demonstrate radiographic responses; at best, 2 patients had stable disease. Median overall survival was 5.5 months (95% CI: 2.3 to 10.8), and median progression-free survival was 1.8 months (95% CI: 1.4 to 1.9). The most common grade 3-4 treatment-related adverse events were fever/chills, influenza-like symptoms, and lymphopenia. No treatment-related deaths were reported. Qualitative analysis of immunohistochemical staining of paired tumor biopsies did not demonstrate significant immune infiltration after treatment, except for one patient who had exceptional survival (26.0 months). Immune analysis of peripheral blood mononuclear cells showed an increase of PD-1highKi67highCD8+ T cells and HLA-DRhigh T cells after VB-111 priming dose. Plasma cytokines interleukin-10 and tumor necrosis factor-alpha increased after treatment with both drugs.ConclusionIn patients with MSS CLM, VB-111 and nivolumab did not improve overall response rate or survival but were tolerated with minimal toxicities. While challenging to distinguish between antiviral or antitumor, correlative studies demonstrated an immune response with activation and proliferation of CD8+ T cells systemically that was poorly sustained.Trial registration numberNCT04166383.
引用
收藏
页数:13
相关论文
共 35 条
  • [31] A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
    Chen, Can
    Chen, Minjun
    Bai, Yuju
    Li, Yajun
    Peng, Jie
    Yao, Biao
    Feng, Jiangping
    Zhou, Jian-Guo
    Ma, Hu
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [32] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
    Bi, Feng
    Dong, Jian
    Jin, Chuan
    Niu, Zuoxing
    Yang, Wenhui
    He, Yifu
    Yu, Dajun
    Sun, Meili
    Wang, Teng
    Yin, Xianli
    Zhang, Ruixing
    Chen, Kehe
    Wang, Keming
    Wang, Zhiwu
    Li, Wei
    Zhang, Zhongtao
    Zhang, Hangyu
    Guo, Qunyi
    Wang, Xin
    Han, Lei
    Zhang, Xizhi
    Shen, Wei
    Zhang, Liangming
    Ying, Jieer
    Wu, Miao
    Hu, Weiguo
    Li, Zeng
    Li, Xiaofen
    Feng, Wenlei
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [33] Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
    Koonrungsesomboon, Nut
    Ngamphaiboon, Nuttapong
    Townamchai, Natavudh
    Teeyakasem, Pimpisa
    Charoentum, Chaiyut
    Charoenkwan, Pimlak
    Natesirinilkul, Rungrote
    Sathitsamitphong, Lalita
    Ativitavas, Touch
    Chaiyawat, Parunya
    Klangjorhor, Jeerawan
    Hongeng, Suradej
    Pruksakorn, Dumnoensun
    BMC CANCER, 2020, 20 (01)
  • [34] Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
    Nut Koonrungsesomboon
    Nuttapong Ngamphaiboon
    Natavudh Townamchai
    Pimpisa Teeyakasem
    Chaiyut Charoentum
    Pimlak Charoenkwan
    Rungrote Natesirinilkul
    Lalita Sathitsamitphong
    Touch Ativitavas
    Parunya Chaiyawat
    Jeerawan Klangjorhor
    Suradej Hongeng
    Dumnoensun Pruksakorn
    BMC Cancer, 20
  • [35] Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
    Dong, Qian
    Diao, Yanwen
    Sun, Xin
    Zhou, Yang
    Ran, Jialing
    Zhang, Jingdong
    BMJ OPEN, 2022, 12 (04):